Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;50(8):1075-82.
doi: 10.1038/bmt.2015.106. Epub 2015 May 11.

High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma

T M Wildes  1 , J D Finney  2 , M Fiala  1 , F Gao  3 , R Vij  1 , K Stockerl-Goldstein  1 , K R Carson  1 , J Mikhael  4 , G Colditz  5
Affiliations

High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma

T M Wildes et al. Bone Marrow Transplant. 2015 Aug.

Abstract

Randomized trials showing that high-dose therapy with autologous stem cell transplant (ASCT) improved the overall survival (OS) in multiple myeloma (MM) excluded patients over age 65. To compare the outcomes of older adults with MM who underwent ASCT with non-transplant strategies, we identified 146 patients aged 65-77 with newly diagnosed MM seen in the Washington University School of Medicine from 2000 to 2010. Survival among patients who did (N=62) versus did not (N=84) undergo ASCT was compared using Cox proportional hazards modeling, controlling for comorbidities, Eastern Cooperative Oncology Group performance status (PS) and the propensity to undergo ASCT. Median age was 68 years (range 65-77). PS and comorbidities did not differ significantly between those who did versus those who did not undergo ASCT. Median OS was significantly longer in patients who underwent ASCT than in those who did not (median 56.0 months (95% confidence intervals (CIs) 49.1-65.4) versus 33.1 months (24.3-43.1), P=0.004). Adjusting for PS, comorbidities, Durie-Salmon stage and the propensity to undergo ASCT, ASCT was associated with superior OS (HR for mortality 0.52 (95% CI 0.30-0.91), P=0.02). In a cohort of older adults with MM, undergoing ASCT was associated with a nearly 50% lower mortality, after controlling for PS, comorbidities, stage and the propensity to undergo ASCT.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors have no relevant conflicts of interest.

Figures

Figure 1
Figure 1
Overall survival of entire cohort by treatment
Figure 2
Figure 2
Overall survival of 48 propensity-score matched pairs
Figure 3
Figure 3
Overall survival, stratified by age group
Figure 4
Figure 4
12-month landmark analysis, overall survival
See this image and copyright information in PMC

References

    1. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation. Journal of Clinical Oncology. 2009;27(17):2758–2765. - PubMed
    1. Pulte D, Gondos A, Brenner H. Improvement in Survival of Older Adults with Multiple Myeloma: Results of an Updated Period Analysis of SEER Data. Oncologist. 2011;16(11):1600–1603. - PMC - PubMed
    1. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128. - PMC - PubMed
    1. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. - PubMed
    1. Klepin HD, Hurd DD. Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions? Bone Marrow Transplantation. 2006;38(9):585–592. - PubMed

Publication types